Page last updated: 2024-09-03

lestaurtinib and MEA 2b

lestaurtinib has been researched along with MEA 2b in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ball, DW; Denmeade, SR; Dionne, C; Jones-Bolin, S; Nelkin, BD; Park, JI; Rosen, M; Ruggeri, B; Strock, CJ	1

Other Studies

1 other study(ies) available for lestaurtinib and MEA 2b

Article	Year
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer research, 2003, Sep-01, Volume: 63, Issue:17 Topics: Animals; Carbazoles; Carcinoma, Medullary; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Furans; Growth Inhibitors; Humans; Indoles; Male; Mice; Mice, Nude; Multiple Endocrine Neoplasia Type 2b; Mutation; Oncogene Proteins; Phosphorylation; Prodrugs; Proto-Oncogene Proteins c-ret; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2003

Article

Year

CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.

Cancer research, 2003, Sep-01, Volume: 63, Issue:17

Topics: Animals; Carbazoles; Carcinoma, Medullary; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Furans; Growth Inhibitors; Humans; Indoles; Male; Mice; Mice, Nude; Multiple Endocrine Neoplasia Type 2b; Mutation; Oncogene Proteins; Phosphorylation; Prodrugs; Proto-Oncogene Proteins c-ret; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2003